This reagent inactivates chymotrypsin with an apparent second-order rate constant of about 2.9 x IO'M-'. s-'. Additionally, it also has a very strong affinity for chymotrypsin since it binds to the enzyme before covalent bond formation with an apparent Ki of 3.4 x lo-' M. Furthermore, this inactivator comes very close to fulfilling the requirements for a model mechanism-based inhibitor as the observed turnover rate or partition ratio of 1.7 is very close to the ideal value of unity for stoichiometric inactivation.
The design of suicide substrates for proteolytic enzymes has provided a considerable challenge to the synthetic chemist. Much of this research has focused on wellcharacterized enzymes of the serine protease class (for a recent review see, e.g., Walsh, 1984) . For example, haloenol lactones, 6-chloro-2-pyrones and chloromethyl coumarins have all provided enzyme-activated irreversible inhibitors for chymotrypsin. The development of mechanism-based inhibitors of the peptidases involved in the processing and metabolism of neuropeptides would provide useful tools for exploring the physiological functions of these enzymes. This review will describe progress made in the purification and characterization of neuropeptide-metabolizing enzymes as well as strategies that can be employed for their inhibition.
Suicide substrates for proteolytic enzymes
With the initial design of suicide substrates in the early 197Os, most of the enzymes inhibited were those that catalysed the formation of carbanion intermediates or carried out redox transformations. Less success was achieved with proteolytic enzymes largely because the process of group transfer to water acting as a nucleophile was far less convenient for the designer of suicide substrates. The major advance in this direction came with the discovery of clavulanate as a suicide inhibitor of the serine enzyme p-lactamase. Shortly afterwards it proved possible to develop suicide substrates for other serine enzymes and particularly for chymotrypsin by concentrating on the acyl-enzyme stage of the reaction.
A particular example is provided by the haloenol lactones which can function as enzyme-activated irreversible inhibitors for chymotrypsin (Daniels et al., 1983) . Acyl transfer to the active-site serine releases a halomethyl ketone that remains in the active site during the Abbreviation used: GEMSA, guanidinoethylmercaptosuccinic acid.
Vol. 14 lifetime of the acyl enzyme, where it can alkylate an accessible nucleophilic residue.
In the field of neuropeptide metabolism, peptidases of various classes are found: serine enzymes, thiol proteases, Zn2' -peptidases. Some of these enzymes have now been obtained in highly purified form (see below) and potent inhibitors are available including transition-state analogues and active-site-directed irreversible inhibitors. The development of enzyme-activated inhibitors, particularly for Zn2+ -peptidases, would provide a valuable addition to the armoury of inhibitors currently available and could be useful for elucidating the physiological role of individual peptidases.
Peptide-metabolizing enzymes
The diversity of peptides that function in a regulatory capacity is only just being realized. Currently more than 40 peptides have been identified as neurotransmitters or neuromodulators in the central nervous system (see, e.g., Iversen, 1985) . Despite this diversity, common mechanisms appear to have evolved for the processing of these various peptides from their precursor molecules and for their inactivation at the cell surface (for a review see Turner et al., 1985) .
The precise identity of the enzymes involved in the proteolytic processing of precursor forms of neuropeptides remains to be clarified (for reviews see Loh et al., Turner, 1984) . However, initial processing can occur at either single or paired basic residues and both serine proteases (e.g. members of the kallikrein family) (Roberts & Pritchett, 1984) or thiol proteases have been implicated in this process. Selective inhibitors of these processing enzymes have yet to be developed. Cleavage at a basic residue releases a peptide with lysine or arginine at the C-terminus. The removal of this basic residue requires the action of an enzyme that has been described as 'enkephalin convertase' or 'carboxypeptidase B-like' (Fricker & Snyder, 1982) . However, it is not specific for enkephalin and may be involved in the processing of a range of peptide hormones. For this enzyme, a selective active-site-directed inhibitor is available, guanidinoethylmercaptosuccinate (GEMSA) BIOCHEMICAL SOCIETY TRANSACTIONS (Strittmatter et al., 1984) . The affinity of this inhibitor (K, = 9 n~) for the enzyme is sufficiently high that
[3H]GEMSA can be used for autoradiographic localization of the enzyme in tissue sections. Such studies, together with immunocytochemical investigations, have revealed that the enzyme is localized in many peptidergic neurons (Strittmatter et al., 1984; Hook et al., 1985) .
Plasma membrane peptidase
At least three identified peptidases have been implicated in the extracellular metabolim of peptides. These are endopeptidase-24.11 ('enkephalinase'), angiotensin converting enzyme (peptidyl dipeptidase A) and aminopeptidase N (see, e.g., Matsas et al., 1985 . They are all 'ecto-enzymes' in that their active sites are exposed on the extracellular face of the membrane. They are also all Zn2+ -metallopeptidases. The classical roles for angiotensin converting enzyme are the inactivation of bradykinin and the hydrolysis of angiotensin I to form the vasoactive peptide angiotensin 11. More recently the enzyme has been shown to hydrolyse the amidated peptides substance P and luliberin (Yokosawa et al., 1983; Skidgel & Erdos, 1985) . In these cases the enzyme displays endopeptidase character, perhaps reflecting a different mode of binding of substrate to the active site. Angiotensin converting enzyme can now be purified to homogeneity in good yield by affinity chromatography on immobilized lisinopril, an inhibitor of the enzyme (Bull et al., 1985) . Using this technique, 50pg of protein can be obtained from 200g of pig kidney in a single step . Endopeptidase-24.11 has also been purified to homogeneity in our laboratory, in this case by employing affinity chromatography using an immobilized monoclonal antibody (Relton et al., 1983) . Thus, substantial quantities of these enzymes are now available for both structural and inhibitor studies.
Design of peptidase inhibitors
Examples of some selective inhibitors of membrane peptidases are given in Table 1 . The design of such inhibitors has relied on the structural detail that is available for two related peptidases, carboxypeptidase A and thermolysin. Inhibitors of angiotensin converting enzyme have found wide applicability as anti-hypertensive drugs, the most generally used being captopril. The features of this compound that provide potent and selective inhibition (Ki = 2 n~) are (i) a thiol group as a zinc-ion ligand, (ii) a prolyl residue which occupies the position of a C-terminal substituent in a 'good' substrate. A terminal prolyl residue is unfavourable for endopeptidase-24.11 and therefore captopril is a relatively weak inhibitor of this enzyme. Side effects of captopril therapy have led to the design of new classes of angiotensin converting enzyme inhibitors of which the most promising are the non-thiol-containing N-carboxymethyldipeptides such as enalapril (Patchett et al., 1980) . There is some evidence that these inhibitors may function as transition state analogues (Patchett et al., 1980) in which a carboxyl, an NH and an R group are arranged in tetrahedral geometry around the scissile peptide bond. Together, their binding energies replace the Znz+ /SH interaction that makes captopril such an effective inhibitor. Other recently developed transition state inhibitors of angiotensin converting enzyme include a family of peptidederived amino alcohols (Gordon et al., 1985) . Alternatively, compounds such as chlorambucil have been used as active-site-directed irreversible inhibitors of the enzyme (Harris & Wilson, 1982) although no enzymeactivated irreversible inhibitors have yet been reported. A terminal prolyl residue is unfavourable for endopeplytic enzymes, including Zn2+ -peptidases, has recently been provided by Gelb et al. (1985) based on the observation that peptides and amino acid analogues containing aldehyde groups can be potent peptidase inhibitors. In these cases it is the hydrated form of the aldehyde that exists in the active site as a hemiacetal bound to the serine oxygen. The aldehydic peptides appear to function as transition-state analogues. Ketone inhibitors would have an advantage over aldehydes in that specificity can be enhanced by variation of both R-groups of the ketone. However, ketones have a limited tendency to hydrate in solution to form hemi-ketals. Since di-and tri-fluoromethyl ketones hydrate readily, Gelb et al. (1985) have synthesized a number of such fluoroketones as potential peptidase inhibitors. They have successfully devised potent inhibitors of angiotensin converting enzyme, carboxypeptidase A as well as acetylcholinesterase and this approach may have wide applicability. Most of our recent work has focused on endopeptidase-24.11, since this appears to be the enzyme involved in the physiological inactivation of the enkephalins. It may also play a role in the catabolism of the neuropeptides substance P, neurokinins A and B, cholecystokinin and also gastrin-releasing peptide Matsas et al., 1984; Bunnett et al., 1985; . Understanding the active site of this enzyme has been facilitated by its similarities with thermolysin including its sensitivity to inhibition by the natural product, phosphoramidon (see Table 1 ). Crystallographic studies of the thermolysin-phosphoramidon complex (Weaver et al., 1977) have demonstrated that the inhibitor binds at the active site of thermolysin and resembles the presumed transition state for peptide bond hydrolysis. Likewise, the important interaction sites in the phosphoramidon-endopeptidase-24.11 complex are believed to be (i) that between the leucyl side chain of phosphoramidon and the S,' hydrophobic subsite of the enzyme, and (ii) co-ordination of one oxygen of the phosphoryl group of the inhibitor with the active-site zinc of the enzyme. This is analogous to the interaction of the carbonyl oxygen of the scissile peptide bond of the substrate with the active-site zinc ion. In addition, the phosphoramidate functional group has the same geometry as the tetrahedral transition state involved in peptide bond hydrolysis. Indeed a number of phosphoramidates are inhibitors of the endopeptidase (Kam et al., 1979) and other classes of inhibitors are being developed in a number of other laboratories (see, e.g., Turner et al., 1985) . The role of aminopeptidases in neuropeptide metabolism has received far less attention and there are few potent and selective inhibitors of these enzymes.
Thus, as new routes to the synthesis of suicide substrates for proteolytic enzymes become available, Zn2+ -peptidases and other classes of proteases may become susceptible to the action of such compounds. Now that several of the cell-surface membrane peptidases can be purified readily, and in high yield, they become a natural target for the study of such inhibitors. Inhibition of angiotensin converting enzyme has already been shown to be of therapeutic value in the treatment of certain forms of hypertension. The value of inhibitors of other peptidases, such as endopeptidase-24.11, remains to be evaluated.
